Quantcast

Latest Management of cancer Stories

2014-06-17 08:29:05

Side-By-Side Genomic Analysis of Patients' Tumor and TumorGraft Mouse Avatars Before and After Treatment Also to be Conducted NEW YORK and HACKENSACK, N.J., June 17, 2014 /PRNewswire/ -- Icahn School of Medicine at Mount Sinai and Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the initiation of a clinical trial evaluating the use of Champions...

2014-06-16 08:28:29

Company continues to engage leading cancer treatment centers to investigate non-invasive methods of cancer mutation detection in order to advance patient care SAN DIEGO, June 16, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time...

2014-06-12 23:14:11

Beneufit’s cFIT™ system allows physicians to prescribe exercise and quantify the impact of specifically followed exercise programs to quality of life in cancer survivors. San Francisco, CA (PRWEB) June 12, 2014 Beneufit’s cFIT™ was selected as a semifinalist to move on to the second phase of the LIVESTRONG Foundation’s inaugural Big C competition, aiming to change the way the world lives with cancer. cFIT, that applies data-driven exercise protocols to help patients manage...

2014-06-10 16:26:49

SCHAUMBURG, Ill., June 10, 2014 /PRNewswire-USNewswire/ -- Extensive clinical experience suggests that hyperthermic intraperitoneal chemotherapy (HIPEC) may play an important role in the ongoing treatment of colorectal cancer patients with peritoneal carcinomatosis (CRCPC). However, there is no established nonsurgical process to select patients for HIPEC treatment as part of recommended standard of care or for clinical trial inclusion....

2014-06-10 08:29:31

Successful collaboration with AstraZeneca includes two novel cancer drugs in clinical development CARLSBAD, Calif., June 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-AR(Rx) in patients with cancer. Isis earned a $15 million milestone payment associated with the clinical advancement of ISIS-AR(Rx). ISIS-AR(Rx) is an antisense drug designed to treat patients with prostate cancer by...

2014-06-04 11:26:06

American Heart Association Study Highlights: -About 12 percent of older breast cancer patients developed heart failure within three years, often as a result of the cancer drugs and treatments. -Only a third of older breast cancer patients saw a cardiologist within 90 days of developing heart problems. -Those who saw a cardiologist were more likely to receive standard drugs for heart failure than those who didn’t. Only a third of older breast cancer patients saw a cardiologist...

2014-06-03 15:54:17

Rice University Animal tests show Rice-developed technology effective against aggressive cancer The first preclinical study of a new Rice University-developed anti-cancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells -- often by blowing them apart -- without harming surrounding normal organs. The research, which is available online this week Nature Medicine, reports that Rice's "quadrapeutics" technology...

2014-06-03 12:15:53

Yale University A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. Yale Cancer Center played a key role in the study, the results of which will be presented Saturday, May 31 at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago. The trial included 68 people with previously...

2014-06-03 08:32:24

Two Studies Presented at ASCO® Demonstrate Company's Ability to Develop Tests to Predict Disease Aggressiveness Across Various Cancers REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX(®) test and a new 16-gene panel to predict disease aggressiveness and clinical outcomes in prostate and renal cancers, respectively. These results, presented at the American...

2014-06-02 08:31:43

Results indicate that it's possible for breast cancer patients to receive adequate doses of radiation therapy while undergoing patient-controlled tissue expansion as part of the breast reconstruction process PALO ALTO, Calif., June 2, 2014 /PRNewswire/ -- AirXpanders Inc., a company developing novel technology for women who require tissue expansion for breast reconstruction following a mastectomy, today reported published results that show that acceptable levels of radiation can be...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related